Financial Information

Capital Market Release


PTA-News: Dr. Hönle AG: Hoenle Group achieves EBITDA of EUR 3.6 million with EUR 69.8 million in sales after nine months

07.08.2025

Gilching (pta008/07.08.2025/08:30) - * Hönle Group achieves revenue of €69.8 million (-3%) in a difficult market environment in the first nine months * EBITDA is €3.6 million (-12%) * Operating cash flow of €3.7 million generated

read more ...

 

PTA-News: Dr. Hönle AG: Business activity picks up in the second quarter

08.05.2025

Gilching (pta012/08.05.2025/08:30) - * Hönle Group increases revenue from €21.4 million in the first quarter to €25.8 million in the second quarter * Discontinuation of unprofitable product lines and initiated cost-cutting measures are showing results * EBITDA increases from €2.6...

read more ...

 

PTA-News: Dr. Hönle AG: Hoenle Group starts new financial year as planned and confirms outlook for full financial year

25.02.2025

Gilching (pta008/25.02.2025/08:45) - * Q1 sales of €21.4 million below previous year's figure of €23.8 million due to structural and economic effects * Cost-cutting measures introduced are showing initial positive effects * EBITDA increases from €0.6 million to €1.0 million *...

read more ...

 

Adhoc Release


PTA-Adhoc: Dr. Hönle AG: Hoenle Group adjusts forecast for financial year 2024/25

05.08.2025

Gilching (pta011/05.08.2025/08:55) - The Management Board had expected revenue of €95 million to €105 million for the Hoenle Group in the 2024/25 financial year and an operating result before depreciation and amortization (EBITDA) significantly higher than the adjusted EBITDA of the...

read more ...

 

PTA-Adhoc: Dr. Hönle AG: Hönle Group confirms positive operating result for financial year 2023/24, but special effects impact EBIT

21.11.2024

Gilching (pta014/21.11.2024/10:15) - The Management Board forecasted sales of around €100 million and a positive operating result (EBIT) for the Hönle Group for the 2023/24 financial year. Based on current knowledge, the Management Board assumes that the Hönle Group achieved a positive...

read more ...

 

PTA-Adhoc: Dr. Hönle AG: Adjustment of the outlook for the 2023/24 financial year

30.04.2024

Gilching (pta002/30.04.2024/00:40) - As communicated in the last capital market statement, the Management Board continues to assume that there will be an upturn in business activities in the second half of the financial year. However, the increase in sales and earnings will be weaker than...

read more ...

 

Find more Articles in our archives.

Archives

 

 

Facts & Figures

Revenues, EBITDA and operating cash flow in T€; Employees data at the end of fiscal year

7 Good Reasons

  1. Leading Market Position
  2. Expansion in Existing Markets
  3. Technological Lead
  4. Hönle as a Process Accelerator
  5. Expansion in Growth Markets
  6. Internationalization
  7. Strong Partners
show more

1. Leading Market Position

Dr. Hönle AG is among the global leaders in the area of UV technology for industrial applications. We are a pace setter in UV technology and in the development of new applications. Our clientele stands for competence and innovation capability. Our customers include leading companies from all target industries. Manroland, Durst, Philips and Krones are working with Hönle equipment.


2. Expansion in Existing Markets

We utilize the benefits of industrial UV technology in the optimization of many production processes in the most diverse of industries. Thus, for example the use of UV-reactive colours yields significant time savings and the production of first-class end products. The 100% solvent-free paints and varnishes do not pose any hazards to humans and the environment. This is why traditional production processes are increasingly being replaced by UV-reactive methods.


3. Technological Lead

The number of UV applications is rapidly expanding and the technology is entering an increasing field of applications. Hönle has launched a completely new device for DVD production. We not only continue to develop established technologies but are also setting standards for tapping new application fields in close cooperation with other companies, universities and research institutes.


4. Hönle as a Process Accelerator

The use of UV systems can simplify production processes, raise productivity and enable direct further processing. This simplifies just in time deliveries and thus provides our customers with an important competitive advantage.


5. Expansion in Growth Markets

Industrial adhesives and UV-based digital printing are areas in which our technology plays an increasingly important role. The environmentally friendly sterilization of water also is an important growth market. We will continue to intensify our activities in these fields.


6. Internationalization

Hönle has an international distribution network, which gives us a worldwide presence in close proximity to our customers. In particular, the strong European position provides us with a solid foundation for our continued dynamic internationalization, primarily in the US and Asia. The export shart is more than 50%.


7. Strong Partners

Development partnerships with leading companies, such as in the printing industry, the photovoltaic industry or the consumer electronics business form the foundation for our technological lead. With the development of new methods we ensure our development leadership and mutually benefit from the exchange of experience.

 

show less

Reports & Presentation

Disclaimer

The articles and analyses published on our web pages are intended only for informational purposes and do not represent offers for the purchase or selling of securities or other investment instruments. The present data are compiled to the best of our knowledge and in good faith. With regard to future-related statements neither Dr. Hönle AG nor any of the associated companies can assume responsibility for the occurrence of the forecast. Due to changing general economic conditions or other factors beyond the control of Dr. Hönle AG, future results may differ considerably from the forecast. Irrespective of legal obligations for adjusting forecasts, Dr. Hönle AG does not intend to continually update all statements related to the future.